Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells

Biochemical and Biophysical Research Communications

Volumn 422, Issue 4, 2012, Pages 578-585

  Lee, Kuan Der ^a,b   Pai, Mei Yu ^c   Hsu, Chia Chen ^c   Chen, Chih Cheng ^a,b   Chen, Yao Li ^d   Chu, Pei Yi ^e   Lee, Chia Huei ^f   Chen, Li Tzong ^f   Chang, Jang Yang ^f   Huang, Tim H M ^g   Hsiao, Shu Huei ^c   Leu, Yu Wei ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e ST MARTIN DE PORRES HOSPITAL   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cell death; Chromatin immunoprecipitation; DNA methylation; Epigenetic; Histone modification

Indexed keywords

CASPASE 8; PLATINUM;

ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; HUMAN; HUMAN CELL; HYPOTHESIS; MESENCHYMAL STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STOMACH CANCER;

APOPTOSIS REGULATORY PROTEINS; CALCIUM-BINDING PROTEINS; CELL LINE; CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 84862295663     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.029     Document Type: Article

References (43)

1. Oberst A., Green D.R. It cuts both ways: reconciling the dual roles of caspase 8 in cell death and survival. Nat. Rev. Mol. Cell Biol. 2011, 12:757-763.
2. Bastiaens P. Systems biology: when it is time to die. Nature 2009, 459:334-335.
3. Krieghoff E., Milovic-Holm K., Hofmann T.G. FLASH meets nuclear bodies: CD95 receptor signals via a nuclear pathway. Cell Cycle 2007, 6:771-775.
4. Medema J.P. Life and death in a FLASH nature 1999, 398:756-757.
5. Jiao Y., Cui L., Gao C., et al. CASP8AP2 is a promising prognostic indicator in pediatric acute lymphoblastic leukemia. Leuk. Res. 2012, 36:67-71.
6. Wang L., Zhou C., Wang Z., et al. Dynamic variation of genes profiles and pathways in the hippocampus of ischemic mice. a genomic study. Brain Res. 2011, 1372:13-21.
7. Peter M.E. Programmed cell death: apoptosis meets necrosis. Nature 2011, 471:310-312.
8. Styczynski J., Wysocki M., Debski R., et al. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J. Cancer Res. Clin. Oncol. 2007, 133:875-893.
9. Holleman A., den Boer M.L., de Menezes R.X., et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006, 107:769-776.
10. Koonin E.V., Aravind L., Hofmann K., et al. Searching for FLASH domains. Nature 1999, 401:662-663.
11. Shi Y. Mechanical aspects of apoptosome assembly. Curr. Opin. Cell Biol. 2006, 18:677-684.
12. De Cola A., Bongiorno-Borbone L., Bianchi E., et al. FLASH is essential during early embryogenesis and cooperates with p73 to regulate histone gene transcription. Oncogene 2012, 31:573-582.
13. Campana D. Minimal residual disease in acute lymphoblastic leukemia Hematology. Am. Soc. Hematol. Educ. Program. 2010, 2010:7-12.
14. Flotho C., Coustan-Smith E., Pei D., et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006, 108:1050-1057.
15. Cario G., Stanulla M., Fine B.M., et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005, 105:821-826.
16. Lugthart S., Cheok M.H., den Boer M.L., et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell. 2005, 7:375-386.
17. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer. 2011, 11:726-734.
18. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398.
19. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
20. Hsiao S.H., Huang T.H., Leu Y.W. Excavating relics of DNA methylation changes during the development of neoplasia. Semin. Cancer Biol. 2009, 19:198-208.
21. Hsu C.C., Li H.P., Hung Y.H., et al. Targeted methylation of CMV and E1A viral promoters. Biochem. Biophys. Res. Commun. 2010, 402:228-234.
22. Teng I.W., Hou P.C., Lee K.D., et al. Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res. 2011, 71:4653-4663.
23. Hsiao S.H., Lee K.D., Hsu C.C., et al. DNA methylation of the Trip10 promoter accelerates mesenchymal stem cell lineage determination. Biochem. Biophys. Res. Commun. 2010, 400:305-312.
24. Bender C.M., Pao M.M., Jones P.A. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998, 58:95-101.
25. Cameron E.E., Bachman K.E., Myohanen S., et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21:103-107.
26. Lee O.K., Kuo T.K., Chen W.M., et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103:1669-1675.
27. Chen C.C., Chen L.T., Tsou T.C., et al. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br. J. Cancer. 2007, 97:334-344.
28. Shi H., Wei S.H., Leu Y.W., Rahmatpanah F., Liu J.C., Yan P.S., Nephew K.P., Huang T.H. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression DNA methylation, and histone acetylation. Cancer Res. 2003, 63:2164-2171.
29. Yan P.S., Venkataramu C., Ibrahim A., et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin. Cancer Res. 2006, 12:6626-6636.
30. Leu Y.W., Rahmatpanah F., Shi H., et al. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res. 2003, 63:6110-6115.
31. Vermeulen M., Mulder K.W., Denissov S., et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell 2007, 131:58-69.
32. Taberlay P.C., Kelly T.K., Liu C.C., et al. Polycomb-Repressed Genes Have Permissive Enhancers that Initiate Reprogramming. Cell. 2011, 147:1283-1294.
33. Lin X., Asgari K., Putzi M.J., et al. Reversal of GSTP1 CpG island hypermethylation and reactivation of π-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 2001, 61:8611-8616.
34. Esteller M., Corn P.G., Urena J.M., et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res. 1998, 58:4515-4518.
35. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 2003, 4:351-358.
36. Esteller M., Herman J.G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol. 2002, 196:1-7.
37. Baylin S.B., Esteller M., Rountree M.R., et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001, 10:687-692.
38. Balch C., Huang T.H., Brown R., et al. The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. 2004, 191:1552-1572.
39. Glasspool R.M., Teodoridis J.M., Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br.J. Cancer 2006, 94:1087-1092.
40. Issa J.P. Decitabine. Curr. Opin. Oncol. 2003, 15:446-451.
41. Baker E.K., El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp. Cell Res. 2003, 290:177-194.
42. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br.J. Cancer 2006, 94:179-183.
43. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 2005, 45:629-656.